- Home
- CR vs QGEN Comparison
CR vs QGEN Comparison
Compare CR & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CR | QGEN |
|---|---|---|
| Founded | 1855 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 10.2B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | CR | QGEN |
|---|---|---|
| Price | $186.97 | $51.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $223.40 | $48.84 |
| AVG Volume (30 Days) | 528.9K | ★ 3.2M |
| Earning Date | 01-26-2026 | 02-04-2026 |
| Dividend Yield | 0.54% | ★ 4.66% |
| EPS Growth | 23.76 | ★ 384.27 |
| EPS | ★ 6.26 | 1.94 |
| Revenue | ★ $2,305,000,000.00 | $2,089,999,000.00 |
| Revenue This Year | $28.03 | $7.12 |
| Revenue Next Year | $5.83 | $6.28 |
| P/E Ratio | $30.34 | ★ $26.65 |
| Revenue Growth | ★ 8.15 | 5.65 |
| 52 Week Low | $127.04 | $39.61 |
| 52 Week High | $214.31 | $57.82 |
Technical Indicators
Market Signals| Indicator | CR | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 53.37 |
| Support Level | $174.78 | $51.25 |
| Resistance Level | $192.96 | $54.10 |
| Average True Range (ATR) | 6.98 | 2.27 |
| MACD | -1.87 | -0.35 |
| Stochastic Oscillator | 31.53 | 45.21 |
Price Performance
Historical ComparisonAbout CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).